NUTRA PHARMA CORP. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
NUTRA PHARMA CORP. (NPHC) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $4.50 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-19
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $4.50M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.14M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.05M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.17M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2026-06-30 | $4.50M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $2.14M 10-Q · filed 2026-05-29 |
| 2025-12-31 | $2.05M 10-Q · filed 2026-08-19 |
| 2025-09-30 | $2.17M 10-Q · filed 2026-04-06 |
| 2025-06-30 | $2.13M 10-Q · filed 2026-03-25 |
| 2025-03-31 | $2.08M 10-Q · filed 2026-03-11 |
| 2024-12-31 | $2.04M 10-Q · filed 2026-08-19 |
| 2023-12-31 | $1.87M 10-K · filed 2026-05-20 |
| 2023-03-31 | $2.21K 10-Q · filed 2025-10-16 |
| 2022-12-31 | $6.07K 10-K · filed 2026-02-17 |
| 2022-09-30 | $200.10K 10-Q · filed 2022-11-21 |
| 2022-06-30 | $376.67K 10-Q · filed 2022-08-22 |
| 2022-03-31 | $410.88K 10-Q · filed 2022-05-20 |
| 2021-12-31 | $710.59K 10-K · filed 2025-11-24 |
| 2020-12-31 | $189.54K 10-K · filed 2025-09-03 |